Kytopen & TQ Therapeutics forge partnership to advance next-generation cell therapies
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
The company introduced the ExcelSign E12 and E17 modular patient monitors, the Relife 1000 biphasic defibrillator, and a new OT charting software
The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Subscribe To Our Newsletter & Stay Updated